Literature DB >> 23289026

Bisphosphonates and osteonecrosis: an open matter.

Paolo Vescovi1.   

Abstract

Osteonecrosis of the Jaw (ONJ) in patients on long-term Bisphosphonate Therapy (BPT) is being reported in the last ten years in the literature with increasing frequency. The therapy for this condition is a real dilemma. Temporary suspension of BPT offers no short term benefits, hyperbaric oxygen has no proven efficiency and therefore is not recommended, intermittent or continuous antibiotic with surgical debridement can be beneficial to palliate the symptoms. Er:YAG laser can be used to eliminate necrotic portions of the bone by partial or total resection of the jaws as an alternative to conventional rotary tools. The high degree of affinity of this wavelength for water and hydroxyapatite means the soft tissue and bone can both be treated. The technique can also be used for conservative interventions by gradually evaporating the part of necrotic bone, getting close to the healthy area. One certain advantage of the Er:YAG laser is its bactericidal and biostimulatory action, inducing the healing of the soft tissues and the bone, quicker than in conventional treatments. In conclusion, from our experience, it is possible to observe that an early conservative surgical approach with Er:YAG laser associated to biostimulation, LLLT (Low Level Laser Therapy), for BRONJ could be considered as more efficacious in comparison to medical therapy or other techniques.

Entities:  

Keywords:  biostimulation; bisphosphonates; bone surgery; laser; laser surgery; low level laser therapy; osteonecrosis of the jaw

Year:  2012        PMID: 23289026      PMCID: PMC3536000     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  26 in total

Review 1.  Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients.

Authors:  Paolo Vescovi; Elisabetta Merigo; Marco Meleti; Maddalena Manfredi; Rebecca Guidotti; Samir Nammour
Journal:  J Oral Pathol Med       Date:  2011-09-30       Impact factor: 4.253

2.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

Review 3.  Osteonecrosis of the jaw: who gets it, and why?

Authors:  Ian R Reid
Journal:  Bone       Date:  2008-10-07       Impact factor: 4.398

4.  Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?

Authors:  Luis Junquera; Lorena Gallego
Journal:  J Oral Maxillofac Surg       Date:  2008-07       Impact factor: 1.895

Review 5.  Potential pathophysiological mechanisms in osteonecrosis of the jaw.

Authors:  Regina Landesberg; Victoria Woo; Serge Cremers; Matthew Cozin; Darja Marolt; Gordana Vunjak-Novakovic; Stavroula Kousteni; Srikala Raghavan
Journal:  Ann N Y Acad Sci       Date:  2011-02       Impact factor: 5.691

6.  Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.

Authors:  T Ziebart; F Koch; M O Klein; J Guth; J Adler; A Pabst; B Al-Nawas; C Walter
Journal:  Oral Oncol       Date:  2011-01-17       Impact factor: 5.337

7.  Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series.

Authors:  Matthew S Epstein; Fredrick W Wicknick; Joel B Epstein; James R Berenson; Meir Gorsky
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-11

Review 8.  Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws.

Authors:  John J Freiberger
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases.

Authors:  Paolo Vescovi; Elisabetta Merigo; Maddalena Manfredi; Marco Meleti; Carlo Fornaini; Mauro Bonanini; Jean Paul Rocca; Samir Nammour
Journal:  Photomed Laser Surg       Date:  2008-02       Impact factor: 2.796

View more
  5 in total

Review 1.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

2.  Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.

Authors:  Mario Migliario; Giovanni Mergoni; Paolo Vescovi; Iolanda De Martino; Manuela Alessio; Luca Benzi; Filippo Renò; Vittorio Fusco
Journal:  Dent J (Basel)       Date:  2017-03-16

Review 3.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06

Review 4.  Oral toxicity produced by chemotherapy: A systematic review.

Authors:  Begonya Chaveli-López
Journal:  J Clin Exp Dent       Date:  2014-02-01

5.  Bisphosphonate related osteonecrosis of the jaw: a study of 18 cases associated with fungal infection.

Authors:  V Aftimos; T Zeinoun; R Bou Tayeh; G Aftimos
Journal:  Int J Dent       Date:  2014-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.